Bli medlem
Bli medlem
lakareutangranser

Du är här

2021-11-04

AlzeCure presents at Redeye Life Science Day 2021 on November 11

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company’s latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.

The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021. The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/.

For more information, please contact


Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)


AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
 
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
 
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.

Image Attachments


Martin Jönsson CEO AlzeCure Pharma

Attachments


AlzeCure presents at Redeye Life Science Day 2021 on November 11

Författare MFN